What is the ICD-10 (International Classification of Diseases, 10th Revision) code for a recent Mycoplasma genitalium infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD-10 Code for Recent Mycoplasma Genitalium Infection

The appropriate ICD-10 code for recent Mycoplasma genitalium infection is A63.8 (Other specified predominantly sexually transmitted diseases). This code should be used when documenting a confirmed Mycoplasma genitalium infection since there is no specific ICD-10 code exclusively for this organism.

Background on Mycoplasma Genitalium

  • Mycoplasma genitalium is recognized as an emerging sexually transmitted pathogen that contributes to 10-35% of non-chlamydial non-gonococcal urethritis in men and is associated with cervicitis and pelvic inflammatory disease (PID) in 10-25% of women 1, 2
  • Transmission occurs through direct mucosal contact, and asymptomatic infections are frequent 1, 2
  • M. genitalium is now established as an important cause of persistent and recurrent non-gonococcal urethritis (NGU) in men 3

Clinical Presentation

  • In men, M. genitalium infection typically presents as urethritis with symptoms including dysuria and urethral discharge 1, 2
  • In women, symptoms may include vaginal discharge, dysuria, or symptoms of PID such as abdominal pain and dyspareunia 1, 2
  • M. genitalium can be asymptomatic in both men and women, making it difficult to diagnose without specific testing 4

Diagnostic Considerations

  • Diagnosis of M. genitalium is achievable only through nucleic acid amplification testing (NAAT), as the organism is difficult to isolate in culture 1, 2
  • Testing should ideally include investigation for macrolide resistance mutations, which are increasingly common 2
  • Recent surveillance data indicates macrolide resistance prevalence of 59.1% in the United States, suggesting azithromycin should not be used without resistance testing 5

Coding Guidance

  • Since there is no specific ICD-10 code for Mycoplasma genitalium, the appropriate code is A63.8 (Other specified predominantly sexually transmitted diseases)
  • When documenting, it is important to specify "Mycoplasma genitalium infection" in the clinical notes to ensure clarity
  • Additional symptom-based codes may be used as secondary codes to document specific manifestations (e.g., urethritis, cervicitis, PID)

Treatment Considerations

  • First-line treatment for uncomplicated M. genitalium without macrolide resistance: Azithromycin 500 mg on day one, then 250 mg on days 2-5 2
  • Second-line treatment and treatment for macrolide-resistant infection: Moxifloxacin 400 mg once daily for 7 days 2
  • For complicated infections such as PID or epididymitis: Moxifloxacin 400 mg once daily for 14 days 2

Public Health Implications

  • M. genitalium is considered an emerging STI of public health concern 6
  • Partner notification and treatment are important to prevent reinfection 6
  • The CDC has placed M. genitalium on its Watch List of Antimicrobial Resistance Threats due to increasing resistance patterns 5

References

Research

2016 European guideline on Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2016

Research

2021 European guideline on the management of Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2022

Research

Mycoplasma genitalium: an emerging sexually transmitted pathogen.

The Indian journal of medical research, 2012

Research

Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.